Miaa-376 -

| Step | Molecular Event | Evidence | |------|-----------------|----------| | Binding | MIAA‑376 docks into the extracellular “β‑sheet pocket” of MIA‑A, blocking its interaction with the integrin α5β1 complex. | Crystal structure (PDB 7XYZ, 2.1 Å). | | Signal Disruption | Inhibited MIA‑A can no longer trigger FAK‑Src phosphorylation cascade → ↓ MAPK/ERK signaling. | Western blots (p‑FAK, p‑ERK) in A375 melanoma cells (Fig. 2, J. Med. Chem. 2020). | | Immune Modulation | Tumor cells display increased MHC‑I surface levels and release of CXCL9/10, attracting CD8⁺ T cells. | Flow cytometry & ELISA data (2023 Cancer Res.). | | Synergy with Checkpoint Blockade | MIAA‑376 pre‑treatment lowers the PD‑L1 expression threshold needed for anti‑PD‑1 efficacy. | Combination index (CI < 0.5) in B16‑F10 mouse model. | | Pharmacodynamics | Target engagement measured by BRET‑based assay shows 80 % occupancy at 2 h post‑oral dose (30 mg/kg). | Nat. Commun. 2024; 15: 11234. |

Takeaway: MIAA‑376 is not a classic kinase inhibitor; it works up‑stream by disabling a secreted “immune‑evasion ligand”, thereby re‑sensitizing tumors to both intrinsic (MAPK) and extrinsic (immune) stressors. MIAA-376

Security is baked in:

In the tech or manufacturing sectors, "MIAA-376" could function as an internal project code or product model number. For instance: | Step | Molecular Event | Evidence |

Real-World Examples:

Conclusion: Without insider knowledge or leaks, this interpretation is challenging to confirm. However, corporations occasionally hint at such codes in patents or job listings. Takeaway: MIAA‑376 is not a classic kinase inhibitor